 Subjects must meet all of the following inclusion criteria in order to be eligible for participation in this study. 1. Provide written informed consent prior to any study procedures. 2. Able to understand and comply with planned study procedures and be available for all study visits. 3. Male or non-pregnant female aged 18 to 50, inclusive. 4. Are in good health, as determined by vital signs oral temperature, pulse, and blood pressure, medical history, and targeted physical examination based on medical history.1 Existing medical diagnoses or conditions except those in the Subject Exclusion Criteria must be deemed as stable chronic medical conditions. A stable chronic medical condition is defined as no change in prescription medication, dose, or frequency of medication in the last 3 months 90 days and health outcomes of the specific disease are considered to be within acceptable limits in the last 6 months 180 days. Any change due to change of health care provider, insurance company, or that is done for financial reasons, as long as in the same class of medication, will not be considered a violation of this inclusion criterion. Any change in prescription medication due to improvement of a disease outcome, as determined by the site principal investigator or appropriate sub-investigator, will not be considered a violation of this inclusion criterion. Subjects may be on chronic or as needed prn medications if, in the opinion of the site principal investigator or appropriate sub-investigator, they pose no additional risk to subject safety or assessment of reactogenicity and immunogenicity. Topical, nasal, and inhaled medications with the exception of steroids as outlined in the Subjects Exclusion Criteria, vitamins, and contraceptives are permitted. 5. Vital signs oral temperature, pulse, and blood pressure are all within normal protocol-defined ranges. Note: The normal protocol-defined ranges for vital signs include a oral temperature less than 100.0F, b pulse 50 to 100 bpm, inclusive, c systolic blood pressure 85 to 150 mmHg, inclusive, and d diastolic blood pressure 55 to 90 mmHg, inclusive. 6. Laboratory tests alanine aminotransferase, creatinine, white blood cells, hemoglobin, and platelets are all within normal protocol-defined reference ranges.33 The normal protocol-defined ranges for laboratory tests include a alanine aminotransferase ALT of 32 IUL or less for females or 44 IUL or less for males, b creatinine 1.0 mgdL or less for females or 1.27 mgdL or less for males, c white blood cells WBC between 3.4 x103uL and 10.8 x103uL, inclusive, d hemoglobin 11.1 gdL or greater for females or 12.6 gdL or greater for males, e platelets between 150 x103uL and 379 x103uL, inclusive. Laboratory test results for 2nd and 3rd vaccinations may be at Grade 1 if considered unrelated to study product. 7. Urinalysis with no greater than trace protein and negative for glucose. 8. Female subjects of childbearing potential4 must agree to practice highly effective contraception5 for a minimum of 30 days prior to study product exposure and through 30 days after last vaccination.4 Female subjects who are surgically sterile via tubal sterilization, bilateral oophorectomy or hysterectomy or who have been postmenopausal for greater than 1 year are not considered to be of childbearing potential.5 Note: Highly effective methods of contraception are defined as having low failure rates i.e. less than 1 per year when used consistently and correctly and may include, but are not limited to, abstinence from intercourse with a male partner, monogamous relationship with a vasectomized partner, mal e condoms or diaphragm with spermicide, intrauterine devices, and licensed hormonal methods. 9. Female subjects of childbearing potential must have a negative urine pregnancy test within 24 hours prior to study vaccination. 